Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Bronchial Spasm D001986 18 associated lipids
Morphine Dependence D009021 9 associated lipids
Shock, Septic D012772 11 associated lipids
Cough D003371 19 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Catalepsy D002375 30 associated lipids
Migraine Disorders D008881 11 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Karlsson C et al. Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. 2015 Endocrinology pmid:25549047
Laezza C et al. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. 2010 Endocr. Relat. Cancer pmid:20304978
Maingret F et al. The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. 2001 EMBO J. pmid:11226154
Chemin J et al. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. 2001 EMBO J. pmid:11742980
van der Stelt M et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. 2005 EMBO J. pmid:16107881
Thieme U et al. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. 2014 Jan-Feb Drug Test Anal pmid:24424856
Battista N et al. Analytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices. 2014 Jan-Feb Drug Test Anal pmid:24218186
Jia Y et al. TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence. 2005 Drug News Perspect. pmid:15915217
Sridar C et al. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. 2011 Drug Metab. Dispos. pmid:21289075
Pratt-Hyatt M et al. Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide. 2010 Drug Metab. Dispos. pmid:20702771
Ekins S et al. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. 2007 Drug Metab. Dispos. pmid:17194716
Muccioli GG Endocannabinoid biosynthesis and inactivation, from simple to complex. 2010 Drug Discov. Today pmid:20304091
Farrell EK and Merkler DJ Biosynthesis, degradation and pharmacological importance of the fatty acid amides. 2008 Drug Discov. Today pmid:18598910
González S et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. 2004 Drug Alcohol Depend pmid:15099659
Childers SR and Breivogel CS Cannabis and endogenous cannabinoid systems. 1998 Jun-Jul Drug Alcohol Depend pmid:9716939
Welch SP Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. 1997 Drug Alcohol Depend pmid:9179505
Harada N and Okajima K Inhibition of neutrophil activation by lafutidine, an H2-receptor antagonist, through enhancement of sensory neuron activation contributes to the reduction of stress-induced gastric mucosal injury in rats. 2007 Dig. Dis. Sci. pmid:17211693
Eckardt K et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. 2009 Diabetologia pmid:19089403
Mallat A and Lotersztajn S Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. 2008 Diabetes Metab. pmid:19195630
Rajesh M et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. 2012 Diabetes pmid:22315315
Troy-Fioramonti S et al. Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. 2015 Diabetes pmid:25281429
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Buznikov GA et al. A putative 'pre-nervous' endocannabinoid system in early echinoderm development. 2010 Dev. Neurosci. pmid:19907129
Levin M and Mercola M Expression of connexin 30 in Xenopus embryos and its involvement in hatching gland function. 2000 Dev. Dyn. pmid:10974676
Levin M and Mercola M Gap junctions are involved in the early generation of left-right asymmetry. 1998 Dev. Biol. pmid:9806775
Harvey BS et al. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. 2013 Cytokine pmid:23706402
Harvey BS et al. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. 2014 Cytokine pmid:24238999
Bisogno T et al. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. 2002 Curr. Pharm. Des. pmid:11945157
Leweke FM Anandamide dysfunction in prodromal and established psychosis. 2012 Curr. Pharm. Des. pmid:22716147
Di Marzo T et al. Endocannabinoids: new targets for drug development. 2000 Curr. Pharm. Des. pmid:10903398
Palmer SL et al. Natural and synthetic endocannabinoids and their structure-activity relationships. 2000 Curr. Pharm. Des. pmid:10903399
Fowler CJ "The tools of the trade"--an overview of the pharmacology of the endocannabinoid system. 2008 Curr. Pharm. Des. pmid:18781976
Kreitzer AC and Regehr WG Retrograde signaling by endocannabinoids. 2002 Curr. Opin. Neurobiol. pmid:12049940
Ohno-Shosaku T and Kano M Endocannabinoid-mediated retrograde modulation of synaptic transmission. 2014 Curr. Opin. Neurobiol. pmid:24747340
Di Marzo V et al. Endovanilloid signaling in pain. 2002 Curr. Opin. Neurobiol. pmid:12139983
Di Marzo V et al. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. 1999 Curr. Med. Chem. pmid:10469888
Reggio PH Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. 2010 Curr. Med. Chem. pmid:20166921
Di Marzo V and De Petrocellis L Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. 2010 Curr. Med. Chem. pmid:20166923
Ashton JC et al. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. 2008 Curr. Med. Chem. pmid:18537620
Dainese E et al. Modulation of the endocannabinoid system by lipid rafts. 2007 Curr. Med. Chem. pmid:17979719
Pate DW et al. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. 1995 Curr. Eye Res. pmid:8529418
Izzo AA et al. The gastrointestinal pharmacology of cannabinoids. 2001 Curr Opin Pharmacol pmid:11757815
Rice AS Cannabinoids and pain. 2001 Curr Opin Investig Drugs pmid:11575713
Cravatt BF and Lichtman AH Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. 2003 Curr Opin Chem Biol pmid:12941421
Battista N et al. Endocannabinoids and their involvement in the neurovascular system. 2004 Curr Neurovasc Res pmid:16185189
Guindon J and Beaulieu P The role of the endogenous cannabinoid system in peripheral analgesia. 2009 Curr Mol Pharmacol pmid:20021453
Maccarrone M et al. Endocannabinoid degradation, endotoxic shock and inflammation. 2002 Curr Drug Targets Inflamm Allergy pmid:14561206
Ligresti A et al. Endocannabinoid metabolic pathways and enzymes. 2005 Curr Drug Targets CNS Neurol Disord pmid:16375679
Panagis G et al. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. 2008 Curr Drug Abuse Rev pmid:19630731
Kadoi Y et al. Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats. 2005 Crit. Care Med. pmid:16276190
Després JP The endocannabinoid system: a new target for the regulation of energy balance and metabolism. 2007 Crit Pathw Cardiol pmid:17667864
Nilsson O et al. Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures. 2003 Comp. Biochem. Physiol. C Toxicol. Pharmacol. pmid:14659458
Guindon J and Hohmann AG The endocannabinoid system and pain. 2009 CNS Neurol Disord Drug Targets pmid:19839937
Lambert RC et al. Modulation of neuronal T-type calcium channels. 2006 CNS Neurol Disord Drug Targets pmid:17168746
Khanna IK and Alexander CW Fatty acid amide hydrolase inhibitors--progress and potential. 2011 CNS Neurol Disord Drug Targets pmid:21631410
García-García F et al. Sleep-inducing factors. 2009 CNS Neurol Disord Drug Targets pmid:19689305
Dollery C Investigative clinical pharmacology. 2011 Clin. Pharmacol. Ther. pmid:21862965
Zoerner AA et al. Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma. 2011 Clin. Pharmacol. Ther. pmid:21716266
Busch L et al. Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland. 2006 Clin. Exp. Pharmacol. Physiol. pmid:16487271
Ruginsk SG et al. Anandamide modulates the neuroendocrine responses induced by extracellular volume expansion. 2013 Clin. Exp. Pharmacol. Physiol. pmid:23875874
Barun S et al. Effects of cannabinoid receptor activation on rabbit bisected vas deferens strips. 2005 Clin. Exp. Pharmacol. Physiol. pmid:16173925
Mitchell VA et al. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. 2007 Clin. Exp. Pharmacol. Physiol. pmid:17880375
Tuboly G et al. Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. 2009 Clin. Exp. Pharmacol. Physiol. pmid:19018802
Vogeser M et al. Release of anandamide from blood cells. 2006 Clin. Chem. Lab. Med. pmid:16599845
Schroeder C et al. Circulating endocannabinoid concentrations during orthostatic stress. 2009 Clin. Auton. Res. pmid:19756829
Cui N et al. Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin. 2017 Clin Ther pmid:28291580
Alenmyr L et al. TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo. 2011 Clin Physiol Funct Imaging pmid:21981454
Bátkai S et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. 2004 Circulation pmid:15451779
Hong Z et al. Role of store-operated calcium channels and calcium sensitization in normoxic contraction of the ductus arteriosus. 2006 Circulation pmid:16982938
Gurney AM et al. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. 2003 Circ. Res. pmid:14551239
Fernandez-Patron C et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. 2000 Circ. Res. pmid:11029402
Ahn K et al. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. 2008 Chem. Rev. pmid:18429637
Xie S et al. Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. 2010 Chem. Res. Toxicol. pmid:21049984
Schmid PC et al. Alternative pathways of anandamide biosynthesis in rat testes. 1998 Chem. Phys. Lipids pmid:9631536
Di Scala C et al. Ceramide binding to anandamide increases its half-life and potentiates its cytotoxicity in human neuroblastoma cells. 2017 Chem. Phys. Lipids pmid:28389107
Palmer SL et al. Cannabinergic ligands. 2002 Chem. Phys. Lipids pmid:12505686
Razdan RK and Mahadevan A Recent advances in the synthesis of endocannabinoid related ligands. 2002 Chem. Phys. Lipids pmid:12505687
Kunos G et al. The quest for a vascular endothelial cannabinoid receptor. 2002 Chem. Phys. Lipids pmid:12505689
Wiley JL and Martin BR Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. 2002 Chem. Phys. Lipids pmid:12505690
Schmid HH et al. Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges. 2002 Chem. Phys. Lipids pmid:12505695
Cravatt BF and Lichtman AH The enzymatic inactivation of the fatty acid amide class of signaling lipids. 2002 Chem. Phys. Lipids pmid:12505696
Paria BC et al. Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation. 2002 Chem. Phys. Lipids pmid:12505701
Sandberg A and Fowler CJ Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin. 2005 Chem. Phys. Lipids pmid:15784231
Kotsikorou E et al. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. 2011 Chem. Phys. Lipids pmid:21185816
Reggio PH and Traore H Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. 2000 Chem. Phys. Lipids pmid:11106780
Howlett AC and Mukhopadhyay S Cellular signal transduction by anandamide and 2-arachidonoylglycerol. 2000 Chem. Phys. Lipids pmid:11106782
Schmid HH Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? 2000 Chem. Phys. Lipids pmid:11106783
Hillard CJ and Jarrahian A The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. 2000 Chem. Phys. Lipids pmid:11106786
Kunos G et al. Endocannabinoids as cardiovascular modulators. 2000 Chem. Phys. Lipids pmid:11106789
Schmid PC et al. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. 1997 Chem. Phys. Lipids pmid:9275307
Schmid PC et al. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. 2000 Chem. Phys. Lipids pmid:10669310
Oddi S et al. Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. 2009 Chem. Biol. pmid:19481477
Ahn K et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. 2009 Chem. Biol. pmid:19389627
Godlewski G et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. 2010 Chem. Biol. pmid:21095576
Shekhar C Mixed signals: cannabinoid system offers new therapeutic possibilities as well as challenges. 2011 Chem. Biol. pmid:21609833
Blankman JL et al. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. 2007 Chem. Biol. pmid:18096503
Imming P Fatty pain cures. 2007 Chem. Biol. pmid:18096498
King AR et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. 2007 Chem. Biol. pmid:18096504
Hanus LO Discovery and isolation of anandamide and other endocannabinoids. 2007 Chem. Biodivers. pmid:17712821
Okamoto Y et al. Biosynthetic pathways of the endocannabinoid anandamide. 2007 Chem. Biodivers. pmid:17712822